Docetaxel lipid albumin bound nanoparticles (Luminus Biosciences)

N/A

Report date: 2022/05/19 15:44:57
NME

Base Information

Drug NameDocetaxel lipid albumin bound nanoparticles (Luminus Biosciences)
Drug Alias NameLASSN-DocetaxelLBI-1103
ClassificationRadiation-emitting products > Radioactive diagnostic agentSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitosis inhibitorsTubulin inhibitorsTubulin polymerisation promoters
TargetsTubulin
Therapy Area/IndicationsProstatic NeoplasmsLung NeoplasmsHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLuminus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesLuminus Biosciences Inc
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsLung NeoplasmsHead and Neck Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A